Last Updated: September 24, 2026

Septodont Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SEPTODONT

SEPTODONT has nine approved drugs.

Summary for Septodont

US Patents:	0
Tradenames:	9
Ingredients:	9
NDAs:	9

Drugs and US Patents for Septodont

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Inc	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	078959-001	Aug 30, 2011	AP	RX	No	No		⤷ Start Trial				⤷ Start Trial
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Septodont	ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN	levonordefrin; mepivacaine hydrochloride	INJECTABLE;INJECTION	084697-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Septodont	OCTOCAINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	084048-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Septodont	OCTOCAINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	084048-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Septodont Inc	LIDOCAINE	lidocaine	OINTMENT;TOPICAL	040911-001	May 23, 2011	AT	RX	No	No		⤷ Start Trial				⤷ Start Trial
Septodont	DYCLOPRO	dyclonine hydrochloride	SOLUTION;TOPICAL	200480-001	Nov 20, 2018		RX	No	Yes		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Septodont

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,764,678	⤷ Start Trial
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,569,230	⤷ Start Trial
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,229,630	⤷ Start Trial
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,575,757	⤷ Start Trial
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,872,390	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.